Cayman
Showing 40801–40950 of 45550 results
-
Sulprostone is a metabolism resistant synthetic analog of PGE2.{1993} It is a selective agonist for EP3 receptors with a Ki value of 0.35 nM at the human recombinant EP3-III receptor and an IC50 of 0.01 µM for the inhibition of PGE2 binding.{8322,3390} Sulprostone is a potent stimulator of uterine smooth muscle contractions with high abortifacient activity.{3335,2462}
Brand:CaymanSKU:- Sulprostone is a metabolism resistant synthetic analog of PGE2.{1993} It is a selective agonist for EP3 receptors with a Ki value of 0.35 nM at the human recombinant EP3-III receptor and an IC50 of 0.01 µM for the inhibition of PGE2 binding.{8322,3390} Sulprostone is a potent stimulator of uterine smooth muscle contractions with high abortifacient activity.{3335,2462}
Brand:CaymanSKU:-
Sultriecin is a fungal metabolite originally isolated from S. roseiscleroticus.{46276} It is active against a panel of 15 fungal strains (MICs = 0.8-50 μg/ml). Sultriecin is cytotoxic to B16/F10, HCT116, Moser, P388, A549, and K562 cancer cells (IC50s = 37.7, 1.92, 0.85, 3.8, 4.14, and 0.67 μg/ml, respectively). It also inhibits RNA and protein synthesis in L1210 leukemia cells (IC50s = 5.5 and 2.4 μg/ml, respectively). Sultriecin (0.1-10 mg/kg) increases survival time in a B16/F10 syngeneic mouse melanoma model and a P388 murine leukemia model.
Brand:CaymanSKU:27976 - 2.5 mgAvailable on backorder
Sultriecin is a fungal metabolite originally isolated from S. roseiscleroticus.{46276} It is active against a panel of 15 fungal strains (MICs = 0.8-50 μg/ml). Sultriecin is cytotoxic to B16/F10, HCT116, Moser, P388, A549, and K562 cancer cells (IC50s = 37.7, 1.92, 0.85, 3.8, 4.14, and 0.67 μg/ml, respectively). It also inhibits RNA and protein synthesis in L1210 leukemia cells (IC50s = 5.5 and 2.4 μg/ml, respectively). Sultriecin (0.1-10 mg/kg) increases survival time in a B16/F10 syngeneic mouse melanoma model and a P388 murine leukemia model.
Brand:CaymanSKU:27976 - 500 µgAvailable on backorder
Sumanirole is a dopamine D2 receptor agonist that is selective for D2 over D1, D3, and D4 receptors (Kis = 9.0, >7,140, 1,940, and >2,190 nM, respectively).{22059} It inhibits forskolin-stimulated cAMP accumulation in CHO cells expressing human recombinant D2A receptors (EC50 = 17 nM). Sumanirole decreases plasma prolactin levels in rats when administered at doses greater than or equal to 3.1 µmol/kg and inhibits dopamine neuron firing in the substantia nigra pars compacta (SNPC) in anesthetized rats (ED50 = 2.3 µmol/kg). Sumanirole (≥12.5 µmol/kg, s.c.) increases horizontal locomotor activity in a reserpinized, α-methyl-para-tyrosine (AMPT) rat model of Parkinson’s disease. It also decreases time spent in the open arms of the elevated plus maze and time spent immobile in the forced swim test, indicating anxiolytic- and antidepressant-like activities, respectively, in mice with SNPC lesions when administered at a dose of 0.1 mg/kg.{31907} Sumanirole (≥0.1 mg/kg, s.c.) reduces premature responding, a measure of impulsivity, by rats in the 5-choice serial reaction time test (5CRTT) compared with untreated animals.{39871}
Brand:CaymanSKU:11984 - 1 mgAvailable on backorder
Sumanirole is a dopamine D2 receptor agonist that is selective for D2 over D1, D3, and D4 receptors (Kis = 9.0, >7,140, 1,940, and >2,190 nM, respectively).{22059} It inhibits forskolin-stimulated cAMP accumulation in CHO cells expressing human recombinant D2A receptors (EC50 = 17 nM). Sumanirole decreases plasma prolactin levels in rats when administered at doses greater than or equal to 3.1 µmol/kg and inhibits dopamine neuron firing in the substantia nigra pars compacta (SNPC) in anesthetized rats (ED50 = 2.3 µmol/kg). Sumanirole (≥12.5 µmol/kg, s.c.) increases horizontal locomotor activity in a reserpinized, α-methyl-para-tyrosine (AMPT) rat model of Parkinson’s disease. It also decreases time spent in the open arms of the elevated plus maze and time spent immobile in the forced swim test, indicating anxiolytic- and antidepressant-like activities, respectively, in mice with SNPC lesions when administered at a dose of 0.1 mg/kg.{31907} Sumanirole (≥0.1 mg/kg, s.c.) reduces premature responding, a measure of impulsivity, by rats in the 5-choice serial reaction time test (5CRTT) compared with untreated animals.{39871}
Brand:CaymanSKU:11984 - 10 mgAvailable on backorder
Sumanirole is a dopamine D2 receptor agonist that is selective for D2 over D1, D3, and D4 receptors (Kis = 9.0, >7,140, 1,940, and >2,190 nM, respectively).{22059} It inhibits forskolin-stimulated cAMP accumulation in CHO cells expressing human recombinant D2A receptors (EC50 = 17 nM). Sumanirole decreases plasma prolactin levels in rats when administered at doses greater than or equal to 3.1 µmol/kg and inhibits dopamine neuron firing in the substantia nigra pars compacta (SNPC) in anesthetized rats (ED50 = 2.3 µmol/kg). Sumanirole (≥12.5 µmol/kg, s.c.) increases horizontal locomotor activity in a reserpinized, α-methyl-para-tyrosine (AMPT) rat model of Parkinson’s disease. It also decreases time spent in the open arms of the elevated plus maze and time spent immobile in the forced swim test, indicating anxiolytic- and antidepressant-like activities, respectively, in mice with SNPC lesions when administered at a dose of 0.1 mg/kg.{31907} Sumanirole (≥0.1 mg/kg, s.c.) reduces premature responding, a measure of impulsivity, by rats in the 5-choice serial reaction time test (5CRTT) compared with untreated animals.{39871}
Brand:CaymanSKU:11984 - 5 mgAvailable on backorder
Sumatriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (IC50s = 9.3 and 7.3 nM, respectively).{23129} It also binds to the 5-HT1F receptor (IC50 = 17.8 nM). It induces vasoconstriction in isolated human middle meningeal arteries (EC50 = 89.9 nM), an effect that can be reduced by the 5-HT1B/1D receptor antagonists GR125,743 and GR127,935. Sumatriptan reduces acute, but not chronic, mechanical hyperalgesia in a mouse model of pain induced by nitroglycerin, which is a known migraine trigger in humans.{48340} Formulations containing sumatriptan have been used in the treatment of migraine headache.
Brand:CaymanSKU:- Sumatriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (IC50s = 9.3 and 7.3 nM, respectively).{23129} It also binds to the 5-HT1F receptor (IC50 = 17.8 nM). It induces vasoconstriction in isolated human middle meningeal arteries (EC50 = 89.9 nM), an effect that can be reduced by the 5-HT1B/1D receptor antagonists GR125,743 and GR127,935. Sumatriptan reduces acute, but not chronic, mechanical hyperalgesia in a mouse model of pain induced by nitroglycerin, which is a known migraine trigger in humans.{48340} Formulations containing sumatriptan have been used in the treatment of migraine headache.
Brand:CaymanSKU:- Sumatriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (IC50s = 9.3 and 7.3 nM, respectively).{23129} It also binds to the 5-HT1F receptor (IC50 = 17.8 nM). It induces vasoconstriction in isolated human middle meningeal arteries (EC50 = 89.9 nM), an effect that can be reduced by the 5-HT1B/1D receptor antagonists GR125,743 and GR127,935. Sumatriptan reduces acute, but not chronic, mechanical hyperalgesia in a mouse model of pain induced by nitroglycerin, which is a known migraine trigger in humans.{48340} Formulations containing sumatriptan have been used in the treatment of migraine headache.
Brand:CaymanSKU:- Sumatriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (IC50s = 9.3 and 7.3 nM, respectively).{23129} It also binds to the 5-HT1F receptor (IC50 = 17.8 nM). It induces vasoconstriction in isolated human middle meningeal arteries (EC50 = 89.9 nM), an effect that can be reduced by the 5-HT1B/1D receptor antagonists GR125,743 and GR127,935. Sumatriptan reduces acute, but not chronic, mechanical hyperalgesia in a mouse model of pain induced by nitroglycerin, which is a known migraine trigger in humans.{48340} Formulations containing sumatriptan have been used in the treatment of migraine headache.
Brand:CaymanSKU:-
Sumatriptan-d6 is intended for use as an internal standard for the quantification of sumatriptan (Item No. 14600) by GC- or LC-MS. Sumatriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (IC50s = 9.3 and 7.3 nM, respectively).{23129} It also binds to the 5-HT1F receptor (IC50 = 17.8 nM). It induces vasoconstriction in isolated human middle meningeal arteries (EC50 = 89.9 nM), an effect that can be reduced by the 5-HT1B/1D receptor antagonists GR125743 and GR127935 (Item No. 29651). Sumatriptan reduces acute, but not chronic, mechanical hyperalgesia in a mouse model of pain induced by nitroglycerin, which is a known migraine trigger in humans.{48340} Formulations containing sumatriptan have been used in the treatment of migraine headache.
Brand:CaymanSKU:28202 - 1 mgAvailable on backorder
Immunogen: Recombinant yeast Smt3 amino acids 1-97 • Host: Mouse • Isotype: IgG1 • Applications: ELISA and WB
Brand:CaymanSKU:12021- 500 µgAvailable on backorder
Immunogen: Recombinant yeast Smt3 amino acids 1-97 • Host: Mouse • Isotype: IgG1 • Applications: ELISA and WB
Brand:CaymanSKU:12021- 500 µg The small ubiquitin like modifier (SUMO) protein is similar in structure and function to ubiquitin. However, SUMO does not typically target proteins for degradation as does ubiquitin.{14288,19512,19511,16072} SUMO is involved with the modification of a very diverse array of targets.{15532} Proteins involved with transcriptional regulation, DNA damage repair, genomic stability, nuclear transport, and histone modification are all subject to modification by SUMO.{19512,15532,19513,15531} SUMO typically functions by covalently binding to a target protein, followed by regulation of protein:protein and protein:DNA interactions.{19512} The SUMO family of proteins is highly conserved from yeast to human. Invertebrates contain a single SUMO gene (Smt3 in yeast and smo-1 in C. elegans), with three members of SUMO being identified in vertebrates to date (SUMO-1, SUMO-2 and SUMO-3).{21733}
Brand:CaymanSKU:12021 - 500 µgAvailable on backorder
The Small Ubiquitin Like Modifier (SUMO) protein is similar in structure and function to ubiquitin. However, SUMO does not typically target proteins for degradation as does ubiqutin. {14288,19512,19511,16072} SUMO is involved with the modification of a very diverse array of targets.{15532} Proteins involved with transcriptional regulation, DNA damage repair, genomic stability, nuclear transport, and histone modification are all subject to modification by SUMO.{19512,19513,15531,15532} SUMO typically functions by covalently binding to a target protein, followed by regulation of protein:protein and protein:DNA interactions.{19512} The SUMO family of proteins is highly conserved from yeast to human. Invertebrates contain a single SUMO gene (Smt3 in yeast and smo-1 in C. elegans), with three members of SUMO being identified in vertebrates to date (SUMO-1, SUMO-2 and SUMO-3).{21733}
Brand:CaymanSKU:14697 - 1 eaAvailable on backorder
Immunogen: Recombinant yeast Smt3 amino acid 1-97 • Host: Rabbit • Cross Reactivity: Not tested • Applications: ELISA and WB
Brand:CaymanSKU:14697- 1 eaAvailable on backorder
Immunogen: Recombinant yeast Smt3 amino acid 1-97 • Host: Rabbit • Cross Reactivity: Not tested • Applications: ELISA and WB
Brand:CaymanSKU:14697- 1 ea
Brand:CaymanSKU:32962- 100 µl Brand:CaymanSKU:32962 - 100 µlAvailable on backorder
Brand:CaymanSKU:32962- 100 µlAvailable on backorder
Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3.{17043,17045} It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src.{17045} Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; IC50s = 250 and 50 nM, respectively).{17043,17045} It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC50s = 30 and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day.{17045} Formulations containing sunitinib have been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.
Brand:CaymanSKU:- Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3.{17043,17045} It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src.{17045} Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; IC50s = 250 and 50 nM, respectively).{17043,17045} It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC50s = 30 and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day.{17045} Formulations containing sunitinib have been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.
Brand:CaymanSKU:- Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3.{17043,17045} It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src.{17045} Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; IC50s = 250 and 50 nM, respectively).{17043,17045} It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC50s = 30 and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day.{17045} Formulations containing sunitinib have been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.
Brand:CaymanSKU:- Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3.{17043,17045} It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src.{17045} Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; IC50s = 250 and 50 nM, respectively).{17043,17045} It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC50s = 30 and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day.{17045} Formulations containing sunitinib have been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.
Brand:CaymanSKU:-
Sunitinib-d10 is intended for use as an internal standard for the quantification of sunitinib (Item No. 13159) by GC- or LC-MS. Sunitinib is a small molecule inhibitor of receptor tyrosine kinases, including FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3.{17043,17045} It is at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src.{17045} Sunitinib inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively) as well as phosphorylation of FLT3 and FLT3 carrying the activating internal tandem duplication mutation (FLT3-ITD; IC50s = 250 and 50 nM, respectively).{17043,17045} It decreases VEGF- and FGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC50s = 30 and 700 nM, respectively) and reduces tumor growth in a variety of mouse xenograft models when administered at doses ranging from 20 to 80 mg/kg per day.{17045} Formulations containing sunitinib have been used in the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.
Brand:CaymanSKU:22614 -Out of stock
Supercinnamaldehyde is an activator of the transient receptor potential ankyrin 1 (TRPA1) channel (EC50 = 0.8 µM) and an analog of cinnamaldehyde.{14717} TRPA1 is a nociceptor expressed on sensory neurons and is activated by hot and cold temperatures, mechanical stimuli, and pain.{23938}
Brand:CaymanSKU:21019 -Out of stock
Supercinnamaldehyde is an activator of the transient receptor potential ankyrin 1 (TRPA1) channel (EC50 = 0.8 µM) and an analog of cinnamaldehyde.{14717} TRPA1 is a nociceptor expressed on sensory neurons and is activated by hot and cold temperatures, mechanical stimuli, and pain.{23938}
Brand:CaymanSKU:21019 -Out of stock
Supercinnamaldehyde is an activator of the transient receptor potential ankyrin 1 (TRPA1) channel (EC50 = 0.8 µM) and an analog of cinnamaldehyde.{14717} TRPA1 is a nociceptor expressed on sensory neurons and is activated by hot and cold temperatures, mechanical stimuli, and pain.{23938}
Brand:CaymanSKU:21019 -Out of stock
Significant amounts of superoxide dismutase (SOD) in cellular and extracellular environments are crucial for the prevention of diseases linked to oxidative stress. Mutations in SOD account for approximately 20% of familial amyotrophic lateral sclerosis (ALS) cases. SOD also appears to be important in the prevention of other neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s Diseases.{10355,3934} The reaction catalyzed by SOD is extremely fast, having a turnover of 2 x 106 M−1sec−1 and the presence of sufficient amounts of the enzyme in cells and tissues typically keeps the concentration of superoxide very low.{10331} Quantification of SOD activity is therefore essential in order to fully characterize the antioxidant capabilities of a biological system. The Cayman Chemical SOD Assay kit is a fast and reliable assay for the measurement of SOD activity from plasma, serum, tissue homogenates, and cell lysates. SOD activity is assessed by measuring the dismutation of superoxide radicals generated by xanthine oxidase and hypoxanthine in a convenient 96 well format. The standard curve generated using this enzyme provides a means to accurately quantify the activity of all three types of SOD (Cu/Zn, Mn, and FeSOD). Each kit contains sufficient reagents to assay 41 samples in duplicate and includes assay buffer, sample buffer, radical detector, SOD (standard), xanthine oxidase, a 96 well plate, and complete instructions.
Brand:CaymanSKU:706002 - 480 wellsAvailable on backorder
Significant amounts of superoxide dismutase (SOD) in cellular and extracellular environments are crucial for the prevention of diseases linked to oxidative stress. Mutations in SOD account for approximately 20% of familial amyotrophic lateral sclerosis (ALS) cases. SOD also appears to be important in the prevention of other neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s Diseases.{10355,3934} The reaction catalyzed by SOD is extremely fast, having a turnover of 2 x 106 M−1sec−1 and the presence of sufficient amounts of the enzyme in cells and tissues typically keeps the concentration of superoxide very low.{10331} Quantification of SOD activity is therefore essential in order to fully characterize the antioxidant capabilities of a biological system. The Cayman Chemical SOD Assay kit is a fast and reliable assay for the measurement of SOD activity from plasma, serum, tissue homogenates, and cell lysates. SOD activity is assessed by measuring the dismutation of superoxide radicals generated by xanthine oxidase and hypoxanthine in a convenient 96 well format. The standard curve generated using this enzyme provides a means to accurately quantify the activity of all three types of SOD (Cu/Zn, Mn, and FeSOD). Each kit contains sufficient reagents to assay 41 samples in duplicate and includes assay buffer, sample buffer, radical detector, SOD (standard), xanthine oxidase, a 96 well plate, and complete instructions.
Brand:CaymanSKU:706002 - 96 wellsAvailable on backorder
Suplatast is an antiallergic agent.{53624,53625} It inhibits IL-4 and IL-5 production in conalbumin-stimulated D10.G4.1 murine T helper 2 (Th2) cells in a concentration-dependent manner.{53624} Suplatast (100 mg/kg) inhibits ovalbumin-induced increases in eosinophil and total cell numbers, as well as IL-4, IL-5, and IL-13, but not IFN-γ, levels in bronchoalveolar lavage fluid (BALF) in an ovalbumin-sensitized mouse model of asthma.{53625} It also inhibits ovalbumin-induced increases in ovalbumin-specific IgE in serum and bronchial hyperresponsiveness to methacholine in the ovalbumin-sensitized mouse model of asthma.
Brand:CaymanSKU:30316 - 1 gAvailable on backorder
Suplatast is an antiallergic agent.{53624,53625} It inhibits IL-4 and IL-5 production in conalbumin-stimulated D10.G4.1 murine T helper 2 (Th2) cells in a concentration-dependent manner.{53624} Suplatast (100 mg/kg) inhibits ovalbumin-induced increases in eosinophil and total cell numbers, as well as IL-4, IL-5, and IL-13, but not IFN-γ, levels in bronchoalveolar lavage fluid (BALF) in an ovalbumin-sensitized mouse model of asthma.{53625} It also inhibits ovalbumin-induced increases in ovalbumin-specific IgE in serum and bronchial hyperresponsiveness to methacholine in the ovalbumin-sensitized mouse model of asthma.
Brand:CaymanSKU:30316 - 100 mgAvailable on backorder
Suplatast is an antiallergic agent.{53624,53625} It inhibits IL-4 and IL-5 production in conalbumin-stimulated D10.G4.1 murine T helper 2 (Th2) cells in a concentration-dependent manner.{53624} Suplatast (100 mg/kg) inhibits ovalbumin-induced increases in eosinophil and total cell numbers, as well as IL-4, IL-5, and IL-13, but not IFN-γ, levels in bronchoalveolar lavage fluid (BALF) in an ovalbumin-sensitized mouse model of asthma.{53625} It also inhibits ovalbumin-induced increases in ovalbumin-specific IgE in serum and bronchial hyperresponsiveness to methacholine in the ovalbumin-sensitized mouse model of asthma.
Brand:CaymanSKU:30316 - 50 mgAvailable on backorder
Suplatast is an antiallergic agent.{53624,53625} It inhibits IL-4 and IL-5 production in conalbumin-stimulated D10.G4.1 murine T helper 2 (Th2) cells in a concentration-dependent manner.{53624} Suplatast (100 mg/kg) inhibits ovalbumin-induced increases in eosinophil and total cell numbers, as well as IL-4, IL-5, and IL-13, but not IFN-γ, levels in bronchoalveolar lavage fluid (BALF) in an ovalbumin-sensitized mouse model of asthma.{53625} It also inhibits ovalbumin-induced increases in ovalbumin-specific IgE in serum and bronchial hyperresponsiveness to methacholine in the ovalbumin-sensitized mouse model of asthma.
Brand:CaymanSKU:30316 - 500 mgAvailable on backorder
Suprafenacine is an inhibitor of tubulin polymerization (IC50 = 0.38 μM) with anticancer activity.{54243} It inhibits the proliferation of HeLa, Jurkat, SNU-16, MDA-MB-231, A549, SH-SY5Y, HCT15, and KB-3-1 cells (IC50s = 83-381.2 nM) and P-glycoprotein-enriched KB-VI cells (IC50 = 215.7 nM). Suprafenacine (10 μM) increases phosphorylation of JNK and Bcl-2 and induces apoptosis and cell cycle arrest at the G2/M phase in HeLa cells. Suprafenacine (20 mg/kg) reduces tumor growth in an HCT15 colon adenocarcinoma mouse xenograft model.
Brand:CaymanSKU:31158 - 1 mgAvailable on backorder
Suprafenacine is an inhibitor of tubulin polymerization (IC50 = 0.38 μM) with anticancer activity.{54243} It inhibits the proliferation of HeLa, Jurkat, SNU-16, MDA-MB-231, A549, SH-SY5Y, HCT15, and KB-3-1 cells (IC50s = 83-381.2 nM) and P-glycoprotein-enriched KB-VI cells (IC50 = 215.7 nM). Suprafenacine (10 μM) increases phosphorylation of JNK and Bcl-2 and induces apoptosis and cell cycle arrest at the G2/M phase in HeLa cells. Suprafenacine (20 mg/kg) reduces tumor growth in an HCT15 colon adenocarcinoma mouse xenograft model.
Brand:CaymanSKU:31158 - 10 mgAvailable on backorder
Suprafenacine is an inhibitor of tubulin polymerization (IC50 = 0.38 μM) with anticancer activity.{54243} It inhibits the proliferation of HeLa, Jurkat, SNU-16, MDA-MB-231, A549, SH-SY5Y, HCT15, and KB-3-1 cells (IC50s = 83-381.2 nM) and P-glycoprotein-enriched KB-VI cells (IC50 = 215.7 nM). Suprafenacine (10 μM) increases phosphorylation of JNK and Bcl-2 and induces apoptosis and cell cycle arrest at the G2/M phase in HeLa cells. Suprafenacine (20 mg/kg) reduces tumor growth in an HCT15 colon adenocarcinoma mouse xenograft model.
Brand:CaymanSKU:31158 - 5 mgAvailable on backorder
Suprofen is a non-steroidal anti-inflammatory drug (NSAID) that non-selectively inhibits both isoforms of cyclooxygenase (COX; IC50s = 1.1 and 8.7 µM for COX-1 and COX-2, respectively).{8427,1286}
Brand:CaymanSKU:21350 -Out of stock
Suprofen is a non-steroidal anti-inflammatory drug (NSAID) that non-selectively inhibits both isoforms of cyclooxygenase (COX; IC50s = 1.1 and 8.7 µM for COX-1 and COX-2, respectively).{8427,1286}
Brand:CaymanSKU:21350 -Out of stock
Suprofen is a non-steroidal anti-inflammatory drug (NSAID) that non-selectively inhibits both isoforms of cyclooxygenase (COX; IC50s = 1.1 and 8.7 µM for COX-1 and COX-2, respectively).{8427,1286}
Brand:CaymanSKU:21350 -Out of stock
Suprofen is a non-steroidal anti-inflammatory drug (NSAID) that non-selectively inhibits both isoforms of cyclooxygenase (COX; IC50s = 1.1 and 8.7 µM for COX-1 and COX-2, respectively).{8427,1286}
Brand:CaymanSKU:21350 -Out of stock
Suramin is a polysulfonated naphthylurea that inhibits the binding of calmodulin to recognition sites on the ryanodine receptor-1 (IC50 = 4.9 μM), blocks G protein coupling to GPCRs, and non-selectively antagonizes P2 purinergic receptors (10-100 μM).{23034,23035} Suramin also acts as a non-specific competitor of glycosaminoglycan binding to a variety of targets including TGFβ, PDGF, and FGF and additionally inhibits insulin-like growth factor-l, EGF, PKC activity, TNF, IL-2, transferrin, and Apo-B.{20120} While originally used as an early stage treatment of trypanosome-caused onchocerciasis (African river blindness) and African trypanosomiasis (African sleeping sickness), suramin has been under clinical evaluation for its potential to regress a number of cancer cell lines, including non-small cell lung cancer, advanced breast cancer, hormone refractory prostate cancer, metastatic renal cell cancer, colorectal cancer, and high-grade gliomas.{20120,20123,20121}
Brand:CaymanSKU:11126 - 100 mgAvailable on backorder
Suramin is a polysulfonated naphthylurea that inhibits the binding of calmodulin to recognition sites on the ryanodine receptor-1 (IC50 = 4.9 μM), blocks G protein coupling to GPCRs, and non-selectively antagonizes P2 purinergic receptors (10-100 μM).{23034,23035} Suramin also acts as a non-specific competitor of glycosaminoglycan binding to a variety of targets including TGFβ, PDGF, and FGF and additionally inhibits insulin-like growth factor-l, EGF, PKC activity, TNF, IL-2, transferrin, and Apo-B.{20120} While originally used as an early stage treatment of trypanosome-caused onchocerciasis (African river blindness) and African trypanosomiasis (African sleeping sickness), suramin has been under clinical evaluation for its potential to regress a number of cancer cell lines, including non-small cell lung cancer, advanced breast cancer, hormone refractory prostate cancer, metastatic renal cell cancer, colorectal cancer, and high-grade gliomas.{20120,20123,20121}
Brand:CaymanSKU:11126 - 250 mgAvailable on backorder
The enzyme 15-hydroxy prostaglandin dehydrogenase (15-PGDH) initiates the catabolism of PGs and related eicosanoids.{20452,20456} SW033291 is a potent inhibitor of 15-PGDH (Ki = ~0.1 nM) that has activity in vivo.{29053} It rapidly increases the levels of PGE2 in bone marrow and other tissues in mice after intraperitoneal injection.{29053} SW033291 accelerates hematopoietic recovery in mice receiving bone marrow transplant and promotes tissue regeneration in mouse models of colon and liver injury.{29053}
Brand:CaymanSKU:-Available on backorder
The enzyme 15-hydroxy prostaglandin dehydrogenase (15-PGDH) initiates the catabolism of PGs and related eicosanoids.{20452,20456} SW033291 is a potent inhibitor of 15-PGDH (Ki = ~0.1 nM) that has activity in vivo.{29053} It rapidly increases the levels of PGE2 in bone marrow and other tissues in mice after intraperitoneal injection.{29053} SW033291 accelerates hematopoietic recovery in mice receiving bone marrow transplant and promotes tissue regeneration in mouse models of colon and liver injury.{29053}
Brand:CaymanSKU:-Available on backorder
The enzyme 15-hydroxy prostaglandin dehydrogenase (15-PGDH) initiates the catabolism of PGs and related eicosanoids.{20452,20456} SW033291 is a potent inhibitor of 15-PGDH (Ki = ~0.1 nM) that has activity in vivo.{29053} It rapidly increases the levels of PGE2 in bone marrow and other tissues in mice after intraperitoneal injection.{29053} SW033291 accelerates hematopoietic recovery in mice receiving bone marrow transplant and promotes tissue regeneration in mouse models of colon and liver injury.{29053}
Brand:CaymanSKU:-Available on backorder
The enzyme 15-hydroxy prostaglandin dehydrogenase (15-PGDH) initiates the catabolism of PGs and related eicosanoids.{20452,20456} SW033291 is a potent inhibitor of 15-PGDH (Ki = ~0.1 nM) that has activity in vivo.{29053} It rapidly increases the levels of PGE2 in bone marrow and other tissues in mice after intraperitoneal injection.{29053} SW033291 accelerates hematopoietic recovery in mice receiving bone marrow transplant and promotes tissue regeneration in mouse models of colon and liver injury.{29053}
Brand:CaymanSKU:-Available on backorder
SW044248 is a DNA topoisomerase I inhibitor that exhibits selective cytotoxicity across a panel of 46 non-small cell lung cancer cell (NSCLC) lines (IC50s = ~2 μM for HCC4017, H292, and H1819 cells versus >20 μM for the remaining cell lines).{37220} It induces cleavage of poly(ADP-ribose) polymerase (PARP) and caspase-3 and blocks DNA replication, RNA transcription, and protein translation in HCC4017 susceptible-, but not HBEC30KT resistant-, cells in a dose-dependent manner. SW044248 inhibits the ability of recombinant topoisomerase 1 to relax supercoiled DNA in a dose-dependent manner and topoisomerase 1 knockdown rescues HCC4017 cells from SW044248 cytotoxicity. SW044248 is less cytotoxic against HCC4017 cells transfected with CDKN1, a protein overexpressed in SW044248-resistant NSCLC cells, indicating a role for CDKN1A in SW044248 resistance.
Brand:CaymanSKU:23459 - 10 mgAvailable on backorder
SW044248 is a DNA topoisomerase I inhibitor that exhibits selective cytotoxicity across a panel of 46 non-small cell lung cancer cell (NSCLC) lines (IC50s = ~2 μM for HCC4017, H292, and H1819 cells versus >20 μM for the remaining cell lines).{37220} It induces cleavage of poly(ADP-ribose) polymerase (PARP) and caspase-3 and blocks DNA replication, RNA transcription, and protein translation in HCC4017 susceptible-, but not HBEC30KT resistant-, cells in a dose-dependent manner. SW044248 inhibits the ability of recombinant topoisomerase 1 to relax supercoiled DNA in a dose-dependent manner and topoisomerase 1 knockdown rescues HCC4017 cells from SW044248 cytotoxicity. SW044248 is less cytotoxic against HCC4017 cells transfected with CDKN1, a protein overexpressed in SW044248-resistant NSCLC cells, indicating a role for CDKN1A in SW044248 resistance.
Brand:CaymanSKU:23459 - 5 mgAvailable on backorder
SW155246 is an inhibitor of DNA methyltransferase 1 (DNMT1; IC50 = 1.2 μM).{42214} It is selective for human DNMT1 over murine DNMT3 (IC50 = 38 μM). SW155246 inhibits HeLa and A549 tumor cell growth in a redox-independent manner (IC50s = 8-20 μM). It also inhibits genomic methylation in HeLa cells when used at concentrations ranging from 10 to 18.6 μM.
Brand:CaymanSKU:21865 -Out of stock
SW155246 is an inhibitor of DNA methyltransferase 1 (DNMT1; IC50 = 1.2 μM).{42214} It is selective for human DNMT1 over murine DNMT3 (IC50 = 38 μM). SW155246 inhibits HeLa and A549 tumor cell growth in a redox-independent manner (IC50s = 8-20 μM). It also inhibits genomic methylation in HeLa cells when used at concentrations ranging from 10 to 18.6 μM.
Brand:CaymanSKU:21865 -Out of stock
SW155246 is an inhibitor of DNA methyltransferase 1 (DNMT1; IC50 = 1.2 μM).{42214} It is selective for human DNMT1 over murine DNMT3 (IC50 = 38 μM). SW155246 inhibits HeLa and A549 tumor cell growth in a redox-independent manner (IC50s = 8-20 μM). It also inhibits genomic methylation in HeLa cells when used at concentrations ranging from 10 to 18.6 μM.
Brand:CaymanSKU:21865 -Out of stock
SW155246 is an inhibitor of DNA methyltransferase 1 (DNMT1; IC50 = 1.2 μM).{42214} It is selective for human DNMT1 over murine DNMT3 (IC50 = 38 μM). SW155246 inhibits HeLa and A549 tumor cell growth in a redox-independent manner (IC50s = 8-20 μM). It also inhibits genomic methylation in HeLa cells when used at concentrations ranging from 10 to 18.6 μM.
Brand:CaymanSKU:21865 -Out of stock
SW203668 is an irreversible inhibitor of stearoyl-CoA desaturase (IC50 = 54 nM).{30821} It is selectively cytotoxic to H2122, H460, HCC44, and HCC95 cell lines that express cytochrome P450 (CYP) isoform CYP4F11 over eight other cancer cell lines that lack CYP4F11 in vitro (IC50s = 22-116 and >10,000 nM, respectively) and ectopic expression of CYP4F11 in SW203668-insensitive H1155 cells results in sensitization to SW203668. In vivo, SW203668 reduces tumor growth rate without reducing sebocyte production in the H2122 wild-type and nonobese diabetic severe combined immunodeficiency (NOD-SCID) mouse xenograft models when administered at doses of 20 and 6 mg/kg, respectively.
Brand:CaymanSKU:-Available on backorder
SW203668 is an irreversible inhibitor of stearoyl-CoA desaturase (IC50 = 54 nM).{30821} It is selectively cytotoxic to H2122, H460, HCC44, and HCC95 cell lines that express cytochrome P450 (CYP) isoform CYP4F11 over eight other cancer cell lines that lack CYP4F11 in vitro (IC50s = 22-116 and >10,000 nM, respectively) and ectopic expression of CYP4F11 in SW203668-insensitive H1155 cells results in sensitization to SW203668. In vivo, SW203668 reduces tumor growth rate without reducing sebocyte production in the H2122 wild-type and nonobese diabetic severe combined immunodeficiency (NOD-SCID) mouse xenograft models when administered at doses of 20 and 6 mg/kg, respectively.
Brand:CaymanSKU:-Available on backorder
SW203668 is an irreversible inhibitor of stearoyl-CoA desaturase (IC50 = 54 nM).{30821} It is selectively cytotoxic to H2122, H460, HCC44, and HCC95 cell lines that express cytochrome P450 (CYP) isoform CYP4F11 over eight other cancer cell lines that lack CYP4F11 in vitro (IC50s = 22-116 and >10,000 nM, respectively) and ectopic expression of CYP4F11 in SW203668-insensitive H1155 cells results in sensitization to SW203668. In vivo, SW203668 reduces tumor growth rate without reducing sebocyte production in the H2122 wild-type and nonobese diabetic severe combined immunodeficiency (NOD-SCID) mouse xenograft models when administered at doses of 20 and 6 mg/kg, respectively.
Brand:CaymanSKU:-Available on backorder
Swainsonine is an indolizidine alkaloid naturally found in certain plants including locoweed that inhibits N-linked glycoside hydrolases, preventing the processing of asparagine-linked glycoproteins. It reversibly inhibits lysosomal α-mannosidase and Golgi α-mannosidase II (IC50 = 0.2 μM).{17179} Swainsonine is used to study the role of N-linked glycosylation in cellular processes and has been shown to have antiproliferative and antimetastatic effects on cancer cells in culture and in mice.{17180,17181,17182} The inhibition of α-mannosidase activity in lysosomes produces an accumulation of partially-processed oligosaccharides and glycoproteins, giving rise to lysosomal storage disease. Swainsonine toxicity in herbivores results in a condition known as locoism, characterized by hyperactivity, aggression, stiff and clumsy gait, low head carriage, salivation, seizures, and apparent blindness, culminating in increased miscoordination, weakness and death.
Brand:CaymanSKU:-Out of stock
Swainsonine is an indolizidine alkaloid naturally found in certain plants including locoweed that inhibits N-linked glycoside hydrolases, preventing the processing of asparagine-linked glycoproteins. It reversibly inhibits lysosomal α-mannosidase and Golgi α-mannosidase II (IC50 = 0.2 μM).{17179} Swainsonine is used to study the role of N-linked glycosylation in cellular processes and has been shown to have antiproliferative and antimetastatic effects on cancer cells in culture and in mice.{17180,17181,17182} The inhibition of α-mannosidase activity in lysosomes produces an accumulation of partially-processed oligosaccharides and glycoproteins, giving rise to lysosomal storage disease. Swainsonine toxicity in herbivores results in a condition known as locoism, characterized by hyperactivity, aggression, stiff and clumsy gait, low head carriage, salivation, seizures, and apparent blindness, culminating in increased miscoordination, weakness and death.
Brand:CaymanSKU:-Out of stock
Swainsonine is an indolizidine alkaloid naturally found in certain plants including locoweed that inhibits N-linked glycoside hydrolases, preventing the processing of asparagine-linked glycoproteins. It reversibly inhibits lysosomal α-mannosidase and Golgi α-mannosidase II (IC50 = 0.2 μM).{17179} Swainsonine is used to study the role of N-linked glycosylation in cellular processes and has been shown to have antiproliferative and antimetastatic effects on cancer cells in culture and in mice.{17180,17181,17182} The inhibition of α-mannosidase activity in lysosomes produces an accumulation of partially-processed oligosaccharides and glycoproteins, giving rise to lysosomal storage disease. Swainsonine toxicity in herbivores results in a condition known as locoism, characterized by hyperactivity, aggression, stiff and clumsy gait, low head carriage, salivation, seizures, and apparent blindness, culminating in increased miscoordination, weakness and death.
Brand:CaymanSKU:-Out of stock
Swainsonine is an indolizidine alkaloid naturally found in certain plants including locoweed that inhibits N-linked glycoside hydrolases, preventing the processing of asparagine-linked glycoproteins. It reversibly inhibits lysosomal α-mannosidase and Golgi α-mannosidase II (IC50 = 0.2 μM).{17179} Swainsonine is used to study the role of N-linked glycosylation in cellular processes and has been shown to have antiproliferative and antimetastatic effects on cancer cells in culture and in mice.{17180,17181,17182} The inhibition of α-mannosidase activity in lysosomes produces an accumulation of partially-processed oligosaccharides and glycoproteins, giving rise to lysosomal storage disease. Swainsonine toxicity in herbivores results in a condition known as locoism, characterized by hyperactivity, aggression, stiff and clumsy gait, low head carriage, salivation, seizures, and apparent blindness, culminating in increased miscoordination, weakness and death.
Brand:CaymanSKU:-Out of stock
Swertiamarin is an orally bioavailable secoiridoid glycoside that has been found in E. axillare and has diverse biological activities, including antioxidant, anti-inflammatory, antidiabetic, and hepatoprotective properties.{53028,53029,53030,53031,53032} It scavenges ABTS (Item No. 27317) radicals and hydrogen peroxide (IC50s = 2.83 and 5.7 μM, respectively).{53028} Swertiamarin (50 μg/ml) inhibits nitric oxide (NO) production in IL-1β-stimulated fibroblast-like synoviocytes (FLSs) isolated from rat hindpaw.{53029} Swertiamarin (25 μg/ml) inhibits oleate-induced lipid droplet and triglyceride accumulation in HepG2 cells.{53031} It decreases liver lipid accumulation, ballooning degeneration, and TNF-α and IL-6 levels in a mouse model of fructose-induced nonalcoholic fatty liver disease (NAFLD) when administered at a dose of 50 mg/kg per day.{53032} Swertiamarin (50 mg/kg per day) also decreases fasting blood glucose and serum cholesterol levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).{53030}
Brand:CaymanSKU:27634 - 10 mgAvailable on backorder
Swertiamarin is an orally bioavailable secoiridoid glycoside that has been found in E. axillare and has diverse biological activities, including antioxidant, anti-inflammatory, antidiabetic, and hepatoprotective properties.{53028,53029,53030,53031,53032} It scavenges ABTS (Item No. 27317) radicals and hydrogen peroxide (IC50s = 2.83 and 5.7 μM, respectively).{53028} Swertiamarin (50 μg/ml) inhibits nitric oxide (NO) production in IL-1β-stimulated fibroblast-like synoviocytes (FLSs) isolated from rat hindpaw.{53029} Swertiamarin (25 μg/ml) inhibits oleate-induced lipid droplet and triglyceride accumulation in HepG2 cells.{53031} It decreases liver lipid accumulation, ballooning degeneration, and TNF-α and IL-6 levels in a mouse model of fructose-induced nonalcoholic fatty liver disease (NAFLD) when administered at a dose of 50 mg/kg per day.{53032} Swertiamarin (50 mg/kg per day) also decreases fasting blood glucose and serum cholesterol levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).{53030}
Brand:CaymanSKU:27634 - 100 mgAvailable on backorder
Swertiamarin is an orally bioavailable secoiridoid glycoside that has been found in E. axillare and has diverse biological activities, including antioxidant, anti-inflammatory, antidiabetic, and hepatoprotective properties.{53028,53029,53030,53031,53032} It scavenges ABTS (Item No. 27317) radicals and hydrogen peroxide (IC50s = 2.83 and 5.7 μM, respectively).{53028} Swertiamarin (50 μg/ml) inhibits nitric oxide (NO) production in IL-1β-stimulated fibroblast-like synoviocytes (FLSs) isolated from rat hindpaw.{53029} Swertiamarin (25 μg/ml) inhibits oleate-induced lipid droplet and triglyceride accumulation in HepG2 cells.{53031} It decreases liver lipid accumulation, ballooning degeneration, and TNF-α and IL-6 levels in a mouse model of fructose-induced nonalcoholic fatty liver disease (NAFLD) when administered at a dose of 50 mg/kg per day.{53032} Swertiamarin (50 mg/kg per day) also decreases fasting blood glucose and serum cholesterol levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).{53030}
Brand:CaymanSKU:27634 - 25 mgAvailable on backorder
Swertiamarin is an orally bioavailable secoiridoid glycoside that has been found in E. axillare and has diverse biological activities, including antioxidant, anti-inflammatory, antidiabetic, and hepatoprotective properties.{53028,53029,53030,53031,53032} It scavenges ABTS (Item No. 27317) radicals and hydrogen peroxide (IC50s = 2.83 and 5.7 μM, respectively).{53028} Swertiamarin (50 μg/ml) inhibits nitric oxide (NO) production in IL-1β-stimulated fibroblast-like synoviocytes (FLSs) isolated from rat hindpaw.{53029} Swertiamarin (25 μg/ml) inhibits oleate-induced lipid droplet and triglyceride accumulation in HepG2 cells.{53031} It decreases liver lipid accumulation, ballooning degeneration, and TNF-α and IL-6 levels in a mouse model of fructose-induced nonalcoholic fatty liver disease (NAFLD) when administered at a dose of 50 mg/kg per day.{53032} Swertiamarin (50 mg/kg per day) also decreases fasting blood glucose and serum cholesterol levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).{53030}
Brand:CaymanSKU:27634 - 50 mgAvailable on backorder
Swinholide A is a natural dimeric dilactone macrolide toxin that causes actin depolymerization in cells.{31286,31287} It stabilizes actin dimers and also binds to and severs F-actin filaments.{31286,31288} Swinholide A binds to G-actin in a 1:2 molar ratio and decreases the rate of nucleotide exchange in G-actin.{31287}
Brand:CaymanSKU:19611 -Available on backorder
Swinholide A is a natural dimeric dilactone macrolide toxin that causes actin depolymerization in cells.{31286,31287} It stabilizes actin dimers and also binds to and severs F-actin filaments.{31286,31288} Swinholide A binds to G-actin in a 1:2 molar ratio and decreases the rate of nucleotide exchange in G-actin.{31287}
Brand:CaymanSKU:19611 -Available on backorder
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that upon phosphorylation binds to immunoreceptor tyrosine-based activation motifs (ITAMs) of FcRγ chains and mediates downstream signaling related to platelet function and inflammation.{24052} Syk inhibitor is an oxindole compound that potently blocks Syk activity with an IC50 value of 14 nM and inhibits FcεRI-mediated rat RBL-2H3 basophil cell degranulation (EC50 = 313 nM).{24050} At 2 μM, this compound completely abolishes convulxin-induced platelet aggregation and shape change.{24051}
Brand:CaymanSKU:- Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that upon phosphorylation binds to immunoreceptor tyrosine-based activation motifs (ITAMs) of FcRγ chains and mediates downstream signaling related to platelet function and inflammation.{24052} Syk inhibitor is an oxindole compound that potently blocks Syk activity with an IC50 value of 14 nM and inhibits FcεRI-mediated rat RBL-2H3 basophil cell degranulation (EC50 = 313 nM).{24050} At 2 μM, this compound completely abolishes convulxin-induced platelet aggregation and shape change.{24051}
Brand:CaymanSKU:- Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that upon phosphorylation binds to immunoreceptor tyrosine-based activation motifs (ITAMs) of FcRγ chains and mediates downstream signaling related to platelet function and inflammation.{24052} Syk inhibitor is an oxindole compound that potently blocks Syk activity with an IC50 value of 14 nM and inhibits FcεRI-mediated rat RBL-2H3 basophil cell degranulation (EC50 = 313 nM).{24050} At 2 μM, this compound completely abolishes convulxin-induced platelet aggregation and shape change.{24051}
Brand:CaymanSKU:-
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that upon phosphorylation binds to immunoreceptor tyrosine-based activation motifs and mediates downstream signaling. Syk inhibitor II is a cell-permeable, pyrimidine-carboxamide compound that selectively and reversibly blocks Syk (IC50 = 41 nM) in an ATP-competitive manner.{30344} It is much less potent against PKCε, PKCβII, ZAP-70, Btk, and Itk (IC50s = 5.1, 11, 11.2, 15.5, and 22.6 µM, respectively).{30344} Syk inhibitor II has been shown to prevent FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and to inhibit passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.).{30344}
Brand:CaymanSKU:-Available on backorder
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that upon phosphorylation binds to immunoreceptor tyrosine-based activation motifs and mediates downstream signaling. Syk inhibitor II is a cell-permeable, pyrimidine-carboxamide compound that selectively and reversibly blocks Syk (IC50 = 41 nM) in an ATP-competitive manner.{30344} It is much less potent against PKCε, PKCβII, ZAP-70, Btk, and Itk (IC50s = 5.1, 11, 11.2, 15.5, and 22.6 µM, respectively).{30344} Syk inhibitor II has been shown to prevent FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and to inhibit passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.).{30344}
Brand:CaymanSKU:-Available on backorder
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that upon phosphorylation binds to immunoreceptor tyrosine-based activation motifs and mediates downstream signaling. Syk inhibitor II is a cell-permeable, pyrimidine-carboxamide compound that selectively and reversibly blocks Syk (IC50 = 41 nM) in an ATP-competitive manner.{30344} It is much less potent against PKCε, PKCβII, ZAP-70, Btk, and Itk (IC50s = 5.1, 11, 11.2, 15.5, and 22.6 µM, respectively).{30344} Syk inhibitor II has been shown to prevent FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and to inhibit passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.).{30344}
Brand:CaymanSKU:-Available on backorder
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chains and mediates downstream signaling related to platelet function and inflammation. Syk inhibitor II is a cell-permeable, pyrimidine-carboxamide compound that selectively and reversibly blocks Syk (IC50 = 41 nM) in an ATP-competitive manner.{30344} It is much less potent against PKCε, PKCβII, ZAP-70, Btk, and Itk (IC50s = 5.1, 11, 11.2, 15.5, and 22.6 µM, respectively).{30344} Syk inhibitor II has been shown to prevent FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and to inhibit passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.).{30344}
Brand:CaymanSKU:-Available on backorder
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chains and mediates downstream signaling related to platelet function and inflammation. Syk inhibitor II is a cell-permeable, pyrimidine-carboxamide compound that selectively and reversibly blocks Syk (IC50 = 41 nM) in an ATP-competitive manner.{30344} It is much less potent against PKCε, PKCβII, ZAP-70, Btk, and Itk (IC50s = 5.1, 11, 11.2, 15.5, and 22.6 µM, respectively).{30344} Syk inhibitor II has been shown to prevent FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and to inhibit passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.).{30344}
Brand:CaymanSKU:-Available on backorder
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chains and mediates downstream signaling related to platelet function and inflammation. Syk inhibitor II is a cell-permeable, pyrimidine-carboxamide compound that selectively and reversibly blocks Syk (IC50 = 41 nM) in an ATP-competitive manner.{30344} It is much less potent against PKCε, PKCβII, ZAP-70, Btk, and Itk (IC50s = 5.1, 11, 11.2, 15.5, and 22.6 µM, respectively).{30344} Syk inhibitor II has been shown to prevent FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and to inhibit passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.).{30344}
Brand:CaymanSKU:-Available on backorder
Antigen: native protein purified from bovine brain • Host: rabbit • Cross-Reactivity: (+) human, rat, and mouse synapsin I • Application(s): IF, IHC, IP, and WB
Brand:CaymanSKU:10606- 1 ea Synapsin I plays a key role in synaptic plasticity in brain. This effect is due in large part to the ability of the synapsins to regulate the availability of synaptic vesicles for release. In addition to its role in plasticity, the expression of synapsin I is a precise indicator of synapse formation. Thus, synapsin I immunocytochemistry provides a valuable tool for the study of synaptogenesis. The role of synapsin in synaptic plasticity and in synaptogensis is regulated by phosphorylation.
Brand:CaymanSKU:10606 - 1 eaAvailable on backorder
Antigen: native protein purified from bovine brain • Host: rabbit • Cross-Reactivity: (+) human, rat, and mouse synapsin I • Application(s): IF, IHC, IP, and WB
Brand:CaymanSKU:10606- 1 eaAvailable on backorder
Antigen: native protein purified from bovine brain • Host: rabbit • Cross Reactivity: (+) human, rat, and mouse synapsin I • Application(s): WB
Brand:CaymanSKU:10605- 1 ea Synapsin I plays a key role in synaptic plasticity in brain. This effect is due in large part to the ability of the synapsins to regulate the availability of synaptic vesicles for release. In addition to its role in plasticity, the expression of synapsin I is a precise indicator of synapse formation. Thus, synapsin I immunocytochemistry provides a valuable tool for the study of synaptogenesis. The role of synapsin in synaptic plasticity and in synaptogensis is regulated by phosphorylation.
Brand:CaymanSKU:10605 - 1 eaAvailable on backorder